Teleflex Inc. (TFX) Resolves FDA Corporate Warning Letter Issued in October
Tweet
Share
E-mailGet Alerts TFX Hot Sheet
Join SI Premium – FREE
Teleflex Incorporated (NYSE: TFX) has received formal notification that it has successfully resolved all outstanding issues raised by the FDA in a corporate Warning Letter received by its subsidiary, Arrow International.
The Warning Letter was received in October of 2007, and identified FDA’s observations on a variety of Arrow’s quality systems control measures that occurred prior to Teleflex’s acquisition of Arrow.
The Warning Letter was received in October of 2007, and identified FDA’s observations on a variety of Arrow’s quality systems control measures that occurred prior to Teleflex’s acquisition of Arrow.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819
- CleanCore Solutions to rename itself Zone Frontier Inc. on Aug. 31
- Mosaic sets pricing for tender offers on up to $1.4B in debt
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
